Phenotype distribution and gender-related differences of CYP2E1 activity in a Chinese population

References

• BOUCHER, P., SEREE, E., VIDON, C., DE SOUZA, A. C., VILLARD, P. H., CHAMBON, R., BARRA, Y. and VALLON, J. J., 2000, Dietary lipid affect human ethanol-inducible CYP2E1 gene expression in vivo in mononuclear cells. Life Science, 67, 1307–1316.
   PubMed Web of Science ®Google Scholar
• BURCKART, G. J., FRYE, R. F., KELLY, P., BRANCH, R. A., JAux, A., FUNG, J. J., STARZL, T. E. and VENKATARAMANAN, R., 1998, Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation. Clinical Pharmacology and Therapeutics, 63, 296–302.
   PubMed Web of Science ®Google Scholar
• CARRIER, V., GOASDURR, T., RATANASAVANH, D., MOREL, F., GAUTIER, J. C., GUILLOUZO, A., BEAUNE, P. and BERTHOU, F., 1993, Both cytochromes P450 2E1 and 1A1 are involved in the metabolism of chlorzoxazone. Chemical Research in Toxicology, 6, 852–857.
   PubMed Web of Science ®Google Scholar
• CARRIERE, V., BERTHOU, F., BAIRD, S., BELLOE, C., BEAUNE, P. and DE WAZIERS, I., 1996, Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics, 6, 203–211.
   PubMedGoogle Scholar
• FRYE, R. F., ADEDOYIN, A., MAURO, K., MATZKE, G. R. and BRANCH, R. A., 1998, Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. Journal of Clinical Pharmacology, 38, 82–89.
   PubMed Web of Science ®Google Scholar
• FUHR, U., 2000, Induction of drug metabolising enzymes. Clinical Pharmacokinetics, 38, 493–504.
   PubMed Web of Science ®Google Scholar
• GARTON, K. J., YUEN P., MEINWALD, J., THUMMEL, K. E. and KHARASCH, E. D., 1995, Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metabolism and Disposition, 23, 1426–1430.
   Google Scholar
• GORSKI, J. C., JONES, D. R., WRIGHTON, S. A. and HALL, S. D., 1997, Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica, 27, 243–256.
   PubMed Web of Science ®Google Scholar
• HAN, X. M. and Zuou, H. H., 2000, Polymorphism of CYP450 and cancer susceptibility. Ada Pharmacologica Sinica, 21, 673–679.
   PubMed Web of Science ®Google Scholar
• HANNON-FLETCHER, M. P., OKANE, M. J., MOLES, K. W., BARNETT, Y. A. and BARNETT, C. R., 2001, Lymphocyte cytochrome P450-CYP2E1 expression in human IDDM subjects. Food and Chemical Toxicology, 39, 125–132.
   Google Scholar
• HAYASHI, S., WANTANABE, J. and KAVAJIRI, K., 1991, Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of human cytochrome P4502E1 gene. Journal of Biochemistry, 110, 559–565.
   PubMed Web of Science ®Google Scholar
• HUNT, C. M., STRATER, S. and STAVE, E. M., 1990, Effect of normal aging on the activity of human hepatic cytochrome P450IIEI. Biochemical Pharmacology, 40, 1666–1669.
   PubMed Web of Science ®Google Scholar
• INGELMAN-SUNDBERG, M., JOHANSSON, I., YIN, H., TERELIUS, Y., ELIASSON, E., CLOT, P. and ALBANO, E., 1993, Ethanol-inducible cytochrome P4502E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. Alcohol, 10, 447–452.
   PubMed Web of Science ®Google Scholar
• JOHANSSON, I., LINDROS, K. O., ERIKSSON, H. and INGELMAN-SUNDBERG, M., 1990, Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. Biochemical and Biophysical Research Communications, 173, 331–338.
   Google Scholar
• KHARASCH, E. D. and THUMMEL, K. E., 1993, Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology, 79, 795–807.
   PubMed Web of Science ®Google Scholar
• KHARASCH, E. D., HANKINS, D. C. and Cox, K., 1999a, Clinical isoflurane metabolism by cytochrome P450 2E1. Anesthesiology, 90, 766–771.
   PubMed Web of Science ®Google Scholar
• KHARASCH, E. D., HANKINS, D. C., JUBERT, C., THUMMEL, K. E. and TARADAY, J. K., 1999b, Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Drug Metabolism and Disposition, 27, 717–723.
   PubMed Web of Science ®Google Scholar
• Kim, R. B., O'SHEA, D. and WILKINSON, G. R., 1995 Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphism. Clinical Pharmacology and Therapeutics, 57, 645–655.
   Google Scholar
• Kim, R. B., O'SHEA, D. and WILKINSON, G. R., 1994, Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics, 4,162–165.
   Google Scholar
• KIM, R. B., YAMAZAKI, H., CHIBA, K., O'SHEA, D., MIMURA, M., GUENGERICH, F. P., ISHIZAKI, T., SHIMADA, T. and WILKINSON, G. R., 1996, In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. Journal of Pharmacology and Experimental Therapeutics, 279, 4–11.
   Google Scholar
• KURATA, N., NISHIMURA, Y., IwasE, M., FISCHER, N. E., TANG, B. K., INABA, T. and YASUHARA, H., 1998, Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica, 28, 1041–1047.
   PubMed Web of Science ®Google Scholar
• LE MARCHAND, L., WILKINSON, G. R. and WILKENS, L. R., 1999, Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiology, Biomarkers and Prevention, 8, 495–500.
   PubMed Web of Science ®Google Scholar
• LIN, D. X., TANG, Y. M., PENG, Q., Lu, S. X., AMBROSONE, C. B. and KADLUBAR, F. F., 1998, Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases Ti, P1, and M1 and cytochrome P450 2E1. Cancer Epidemiology, Biomarkers and Prevention, 7, 1013–1018.
   PubMed Web of Science ®Google Scholar
• LOIZOU, G. D. and COCKER, J., 2001, The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Human and Experimental Toxicology, 20, 321–327.
   PubMed Web of Science ®Google Scholar
• LU, S. H., Cum, S. X., YANG, W. X., Hu, X. N., Goo, L. P. and Li, F. M., 1991, Relevance of N-nitrosamines to oesophageal cancer in China. IARC Scientific Publications, 105,11–17.
   Google Scholar
• LUCAS, D., BERTHOU, F., GIRRE, C., POITRENAUD, F. and MENEZ, J. F., 1993, High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 activity in humans. Journal of chromatography, 622, 79–86.
   PubMed Web of Science ®Google Scholar
• LUCAS, D., FAREZ, C., BARDOU, L. G., VAISSE, J., ATTALI, J. R. and VALENSI, P., 1998, Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundamental and Clinical Pharmacology, 12, 553–558.
   PubMed Web of Science ®Google Scholar
• LUCAS, D., FERRARA, R., GONZALEZ, E., BODENEZ, P., ALBORES, A., MANNO, M. and BERTHOU, F., 1999, Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics, 9,377–388.
   PubMedGoogle Scholar
• LUCAS, D., MENEZ, C., GIRRE, C., BERTHOU, F., BODENEZ, P., JOANNET, I., HISPARD, E., BARDOU, L. G. and MENEZ, J. F., 1995, Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. Pharmacogenetics, 5,298–304.
   PubMedGoogle Scholar
• MANYIKE, P. T., KHARASCH, E. D., KALHORN, T. F. and SLATTERY, J. T., 2000, Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clinical Pharmacology and Therapeutics, 67, 275–282.
   PubMed Web of Science ®Google Scholar
• MORIMOTO, M., HAGBJORK, A. L., NAND, A. A., INGELMAN-SUNDBERG, M., LINDROS, K. O., Fu, P. C., ALBANO, E. and FRENCH, S. W., 1993, Role of cytochrome P4502E1 in alcoholic liver disease pathogenesis. Alcohol, 10, 459–464.
   Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., TSUTSUI, M., SATOH, T. and GONZALEZ, F. J., 1995, Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5, 143–150.
   PubMedGoogle Scholar
• O'SHEA, D., Davis, S. N., Kim, R. B. and WILKINSON, G. R., 1994, Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clinical Pharmacology and Therapeutics, 56, 359–367.
   Google Scholar
• PAN, J., HONG, J. Y. and YANG, C. S., 1992, Post-transcriptional regulation of mouse renal cytochrome P450 2E1 by testosterone. Archives of Biochemistry and Biophysics, 299, 110–115.
   PubMed Web of Science ®Google Scholar
• PETER, R., BOCKER, R., BEAUNE, P. H., IWASAKI, M., GUENGERICH, F. P. and YANG, C. S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-45011EI. Chemical Research in Toxicology, 3, 566–573.
   PubMed Web of Science ®Google Scholar
• PRESCOTT, L. F., 2000, Paracetamol, alcohol and the liver. British Journal of Clinical Pharmacology, 49, 291–301.
   PubMed Web of Science ®Google Scholar
• RAUCY, J. L., SCHULTZ, E. D., WESTER, M. R., ARORA, S., JOHNSTON, D. E., OMDAHL, J. L. and CARPENTER, S. P., 1997, Human lymphocyte cytochrome P450 2E1, a putative marker for alcohol-mediated changes in hepatic chlorzoxazone activity. Drug Metabolism and Disposition, 25, 1429–1435.
   PubMed Web of Science ®Google Scholar
• ROTHMAN, N., SMITH, M. T., HAYES, R. B., TRAVER, R. D., HOENER, B., CAMPLEMAN, S., Li, G. L., DOSEMECI, M., LINET, M., ZHANG, L., XI, L., WACHOLDER, S., Lu, W., MEYER, K. B., TITENKO HOLLAND, N., STEWART, J. T., YIN, S. and Ross, D., 1997, Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQ01 609C T mutation and rapid fractional excretion of chlorzoxazone. Cancer Research, 57, 2839–2842.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, cardinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• STREETMAN, D. S., BEATING, J. S. and NAFZIGER, A. N., 2000, Phenotype of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotype. Pharmacogenetics, 10, 187–216.
   PubMedGoogle Scholar
• TAN, W., SONG, N., WANG, G. Q., Liu, Q., TANG, H. J., KADLUBAR, F. F. and LIN, D. X., 2000, Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases Ml, Ti, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiology, Biomarkers and Prevention, 9, 551–556.
   PubMed Web of Science ®Google Scholar
• TANAKA, E., TERADA, M. and MISAWA, S., 2000, Cytochrome P450 2E1: its clinical and toxicological role. Journal of Clinical Pharmacy and Therapeutics, 25, 165–175.
   PubMed Web of Science ®Google Scholar
• UEMATSU, F., Kutuctii, H. and MOTOMIYA, M., 1991, Association between restriction fragment length polymorphism of human cytochrome P4502E1 and susceptibility to lung cancer. Japanese Journal of Cancer Research, 82, 254–256.
   PubMedGoogle Scholar
• UPADHYA, S. C., TIRUMALAI, P. S., BOYD, M. R., MORI, T. and RAVINDRANATH, V., 2000, Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Archives of Biochemistry and Biophysics, 373, 23–34.
   PubMed Web of Science ®Google Scholar
• VESELL, E. S., SEATON, T. D. and A-Rumm, Y. I., 1995, Studies on interindividual variations of CYP2E1 using chlorzaxazone as an in vivo probe. Pharmacogenetics, 5, 53–57.
   Google Scholar
• VIEIRA, I., PASANEN, M., RAUNIO, H. and CRESTEIL, T., 1998, Expression of CYP2E1 in human lung and kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacology and Toxicology, 83, 183–187.
   PubMedGoogle Scholar
• WANDEL, C., NEFF, S., KEPPLER, G., BOHRER, H., STOCKINGER, K., WILKINSON, G. R., WOOD, M. and MARTIN, E., 1997, The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humans. Anesthesia and Analgesia, 85, 924–930.
   PubMed Web of Science ®Google Scholar
• WU, X., Amos, C. I., KEMP, B. L., Sol, H., JIANG, H., WAN, Y. and SPITZ, M. R., 1998, Cytochrome P450 2E1 DraI polymorphisms in lung cancer in minority populations. Cancer Epidemiology, Biomarkers and Prevention, 7, 13–18.
   PubMed Web of Science ®Google Scholar
• YU, Y., TAYLOR, P. R., Li, J. Y., DAWSEY, S. M., WANG, G. Q., Guo, W. D., WANG, W., Liu, B. Q., BLOT, W. J. and SHEN, Q., 1993, Retrospective cohort study of risk-factors for esophageal cancer in Linxian, People's Republic of China. Cancer Causes and Control, 4, 195–202.
   PubMed Web of Science ®Google Scholar
• ZAND, R., NELSON, S. D., SLATTERY, J. T., THUMMEL, K. E., KALHORN, T. F., ADAMS, S. P. and WRIGHT, J. M., 1993, Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clinical Pharmacology and Therapeutics, 54, 142–149.
   PubMed Web of Science ®Google Scholar
• ZHOU, H. H. and Liu, Z. Q., 2000, Ethnic difference in drug metabolism. Clinical Chemistry and Laboratory Medicine, 38, 899–903.
   PubMed Web of Science ®Google Scholar